PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
42.09
+0.67 (+1.62%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close41.42
Open41.48
Bid42.02 x 36100
Ask42.11 x 2900
Day's Range41.47 - 42.19
52 Week Range32.32 - 42.19
Volume24,583,231
Avg. Volume20,264,875
Market Cap246.208B
Beta0.96
PE Ratio (TTM)11.24
EPS (TTM)3.74
Earnings DateOct 29, 2018 - Nov 2, 2018
Forward Dividend & Yield1.36 (3.33%)
Ex-Dividend Date2018-08-02
1y Target Est40.80
Trade prices are not sourced from all markets
  • Motley Fool5 hours ago

    Here’s Why Alnylam’s Shares Are Tumbling

    Alnylam secured a first-in-class approval, but that doesn’t guarantee commercial success.

  • Investor's Business Daily12 hours ago

    Retailer Breaks Out As This Dow Jones Stock Is A New Emerging Winner

    The Dow Jones industrial average led a light yet broad rally in stocks today. Chip stocks weighed on the leading index of growth companies. Pfizer is gaining more traction.

  • 2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
    Motley Fool12 hours ago

    2 Reasons Alnylam Stock Fell on a Landmark Drug Approval

    Investors didn't celebrate Alnylam's first drug approval. Maybe they should have.

  • Investopedia13 hours ago

    Pfizer, at Highest Price in a Decade, May Fall 10%

    Pfizer Inc's ( PFE) stock has surged higher by more than 16% in 2018. Now shares may be due to fall by about 10% based on technical analysis. The technical chart shows Pfizer's stock breaking out at the start of July when it increased above technical resistance at $37 and has risen by more than 13% since.  Now shares are bumping up against a resistance level around $42, that goes back for nearly two decades to late 2001, and that may prove difficult for the stock to rise above.

  • Motley Fool14 hours ago

    3 Tough-Luck Tumbles in Healthcare: Are They Buys?

    Spark Therapeutics, Rite Aid, and Alnylam Pharmaceuticals shares have dropped recently, but that doesn't necessarily make all three stocks worth buying.

  • Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
    Market Realist16 hours ago

    Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead

    Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.

  • Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies
    Bloomberg16 hours ago

    Lifesaving EpiPen Device Still Out of Stock at Many Pharmacies

    Mylan NV’s EpiPen is still hard to find at many pharmacies, three months after U.S. authorities declared that the lifesaving allergy device was in shortage, a survey by Wells Fargo & Co. showed. The finding comes a day after Teva Pharmaceutical Industries Ltd. gained Food and Drug Administration approval to sell a generic version of Mylan’s epinephrine autoinjector. Wells Fargo analysts reached out to 53 pharmacies across the country on Thursday and found that 66 percent were out of stock of Mylan’s EpiPens, not including EpiPen Jr., analyst Davis Maris said in a note Friday.

  • Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic
    Zacks16 hours ago

    Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

    Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

  • Company News For Aug 17, 2018
    Zacks16 hours ago

    Company News For Aug 17, 2018

    Companies in the news are: JD, JCP, PFE and AMZN

  • EpiPen shortage has parents struggling during back-to-school season
    CNBC18 hours ago

    EpiPen shortage has parents struggling during back-to-school season

    The life-saving allergy medicine has had manufacturing disruptions since May, but allergy sufferers and caregivers may find it especially hard to find now, as parents try to stock up to send their kids back to school.

  • If I Had to Buy 1 Stock in August, It Would Be This One
    Motley Fool19 hours ago

    If I Had to Buy 1 Stock in August, It Would Be This One

    This healthcare company appears poised to turn a corner.

  • Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
    Zacks22 hours ago

    Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

    Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.

  • FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
    Market Realistyesterday

    FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

    Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.

  • 3 Terrible Reasons to Sell Pfizer Stock
    Motley Fool2 days ago

    3 Terrible Reasons to Sell Pfizer Stock

    Pfizer's shares have been heating up, but now isn't the time to take profits. Here's why.

  • MYL Stock Down ~3% since Its Q2 2018 Results on August 8
    Market Realist2 days ago

    MYL Stock Down ~3% since Its Q2 2018 Results on August 8

    The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $29.39 on August 15, 2017. Currently, MYL stock is trading above its 50-day moving average of $36.80 but below its 200-day moving average of $39.52. On August 8, MYL stock had declined as much as 7.2% on disappointing second-quarter results that missed analysts’ estimates.

  • Most Analysts Are Optimistic about Vertex Pharmaceuticals
    Market Realist2 days ago

    Most Analysts Are Optimistic about Vertex Pharmaceuticals

    How Is Vertex Pharmaceuticals Positioned in August? On February 12, the FDA approved Vertex Pharmaceuticals’ (VRTX) Symdeko, which is the company’s third cystic fibrosis drug in the US market. Symdeko continues to witness a strong launch in the US market, and demand has risen across the entire range of eligible patients.

  • CNBC2 days ago

    Stocks making the biggest moves premarket: WMT, JD, JCP, BA, CSCO & more

    Comparable-store sales at Walmart U.S. stores rose 4.5 percent from a year earlier, well above the consensus estimate of 2.4 percent. JD.com JD – The China-based internet retailer missed estimates on both the top and bottom lines in its second-quarter earnings report. Investors appear to be focusing on slowing revenue growth rates, with the second quarter's 31.2 percent growth well below the peak of about 60 percent registered in 2015.

  • Should Gilead Be Worried About This New Monthly HIV Medication?
    Motley Fool2 days ago

    Should Gilead Be Worried About This New Monthly HIV Medication?

    The devil is in the undisclosed details.

  • The Wall Street Journal2 days ago

    [$$] Pfizer, BioNTech in $425 Million Flu Vaccine Collaboration

    BioNTech said it will receive $120 million in upfront payments from Pfizer, along with up to $305 million in potential milestone payments. The Mainz, Germany, company said it will also receive up to double-digit tiered royalty payments on worldwide sales if the program reaches commercialization. BioNTech and Pfizer will jointly conduct research-and-development activities on mRNA-based flu vaccines, the companies said.

  • Financial Times2 days ago

    [$$] Teva shares climb after FDA approves its generic EpiPen

    got a shot in the arm on Thursday from the long-awaited approval by US regulators of its generic version of Mylan’s EpiPen allergy injector. Teva’s New York-listed shares were up 6 per cent to $23.83 after the US Food and Drug Administration gave the go-ahead to the Israel-based company.

  • Reuters2 days ago

    Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

    Pfizer (PFE.N) has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday. Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.

  • Reuters2 days ago

    Pfizer bets on biotech flu vaccine in $425 mln BioNTech alliance

    Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday. Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.

  • Investor's Business Daily2 days ago

    FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5%

    FANG stocks were down sharply in afternoon trading Wednesday, with shares of Netflix and Google parent Alphabet down more than 2%.

  • Cramer throws out this tech stock to diversify portfolio
    CNBC Videosyesterday

    Cramer throws out this tech stock to diversify portfolio

    Jim Cramer answers callers' questions about how to diversify their portfolios, including which tech stocks to keep and which to throw out.